Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $50.9 million.

  • ARS Pharmaceuticals' Total Current Liabilities rose 20606.39% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 20606.39%. This contributed to the annual value of $23.4 million for FY2024, which is 88034.3% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Total Current Liabilities of $50.9 million as of Q3 2025, which was up 20606.39% from $45.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Total Current Liabilities high stood at $50.9 million for Q3 2025, and its period low was $2.4 million during Q4 2023.
  • For the 5-year period, ARS Pharmaceuticals' Total Current Liabilities averaged around $15.5 million, with its median value being $11.2 million (2023).
  • Per our database at Business Quant, ARS Pharmaceuticals' Total Current Liabilities crashed by 7400.14% in 2022 and then skyrocketed by 88034.3% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Total Current Liabilities (Quarter) stood at $8.2 million in 2021, then plummeted by 33.5% to $5.4 million in 2022, then tumbled by 56.08% to $2.4 million in 2023, then soared by 880.34% to $23.4 million in 2024, then skyrocketed by 117.05% to $50.9 million in 2025.
  • Its Total Current Liabilities stands at $50.9 million for Q3 2025, versus $45.6 million for Q2 2025 and $27.6 million for Q1 2025.